Founded in 1989, Genetic Technologies Limited is an established Australian-based molecular diagnostics company specialising in women’s health. The Company offers predictive testing and assessment tools to help physicians proactively manage women’s health. The Company’s lead product,BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class.The Company markets BREVAGenplusto healthcare professionals in comprehensive breast health care and imaging centres, as well as to obstetricians/gynaecologists (OBGYNs) and breast cancer risk assessment specialists (such as breast surgeons).
|Bank Name||Genetic Technologies Ltd|
|Industry||Biotechnology: Biological Products|
|Chairman||Dr. Paul Alexander Kasian Ph.D.|
|CEO||Dr. Paul Alexander Kasian Ph.D.|